Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that clinical and preclinical data supporting the role of CAL-101, an oral, p110δ(delta) selective PI3K inhibitor in patients with hematologic malignancies, will be featured in two oral presentations at the upcoming 51^st American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, LA.

CAL-101 oral presentations at the ASH meeting include:

Evidence of Clinical Activity in a Phase 1 Study of CAL-101, an Oral P110δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies

• Presenter: Ian W Flinn, M.D., Ph.D., Director of Hematologic Malignancies Research at the Sarah Cannon Research Institute, Nashville, TN.
• Tuesday, December 8, 2009, 8:15 a.m., Ernest N. Morial Convention Center, Room 260-262
• Oral Session: Lymphoma: Chemotherapy, excluding Pre-Clinical Models - New Treatments
• Abstract #922: http://ash.confex.com/ash/2009/webprogram/Paper23760.html

CAL-101, An Oral p110δ Selective Phosphatidylinositol-3-Kinase (PI3K) Inhibitor for the Treatment of B Cell Malignancies Inhibits PI3K Signaling, Cellular Viability and Protective Signals of the Microenvironment

• Presenter: Brian Lannutti, Ph.D., Calistoga Pharmaceuticals
• Monday, December 7, 2009, 7:45 a.m., Ernest N. Morial Convention Center, Room 243-245
• Oral Session: Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents: Novel Small Molecule Inhibitors In Preclinical Lymphoma Models
• Abstract #286: http://ash.confex.com/ash/2009/webprogram/Paper21880.html